Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, Anirudh Prahallad, Cristina Diaz-de-Heredia

Blood (2024) 144 (20): 2095–2106.

https://doi.org/10.1182/blood.2023022565

Published: 2024

Includes: Supplemental data

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Blood (2024) 144 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2024-198741

Published: 2024

Journal Articles

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Gloria Hidalgo-Gomez, Bárbara Tazón-Vega, Carlos Palacio, Silvia Saumell, María Gabarrós-Subirà, Andres Jerez, Adoracion Blanco, Noemí Martínez-Morgado, Víctor Navarro Garces, Laura Murillo, Pablo Velasco, Thais Murciano, Cristina Díaz De Heredia, Francesc Bosch, Gemma Armengol, Margarita Ortega

Blood (2024) 144 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2024-209957

Published: 2024

Journal Articles

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Blood (2024) 144 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2024-203358

Published: 2024

Journal Articles

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Dr. Peters, Peter Bader, Ulrike Pötschger, M. Akif Yesilipek, Herbert Pichler, Franco Locatelli, Raquel Staciuk, Adriana Balduzzi, Gergely Krivan, Marianne Ifversen, Cristina Díaz De Heredia, Marc Bierings, Jacek Wachowiak, Jean-Hugues Dalle

Blood (2023) 142 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2023-185870

Published: 2023

Journal Articles

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Anita Lawitschka, Jean-Hugues Dalle, Ulrike Pötschger, Helga Arnardottir, Petr Sedlacek, Jochen Büchner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Díaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Franco Locatelli, Christina Peters, Peter Bader

Blood (2023) 142 (Supplement 1): 110.

https://doi.org/10.1182/blood-2023-186850

Published: 2023

Journal Articles

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Krzysztof Kalwak, Peter Bader, Jean-Hugues Dalle, Petr Sedlacek, Jochen Buechner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Diaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Ulrike Poetschger, Dr. Peters, Franco Locatelli

Blood (2023) 142 (Supplement 1): 232.

https://doi.org/10.1182/blood-2023-180728

Published: 2023

Journal Articles

Treatment of Congenital Hypotransferrinemia Patients with Human Apotransferrin Resolves Anemia and Reduces Iron Accumulation

Ilona Kleine Budde, Cristina Díaz De Heredia, Raffaella Mariani, Alberto Piperno, Katja Moser, Mayka Sanchez, Thomas Bodewes, Maya Isaila

Blood (2023) 142 (Supplement 1): 922.

https://doi.org/10.1182/blood-2023-174830

Published: 2023

Journal Articles

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Blood (2023) 142 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2023-187587

Published: 2023

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Blood (2022) 140 (Supplement 1): 12938–12940.

https://doi.org/10.1182/blood-2022-162484

Published: 2022

Journal Articles

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Blood (2022) 140 (Supplement 1): 7754–7756.

https://doi.org/10.1182/blood-2022-164561

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Blood (2022) 140 (Supplement 1): 10895–10896.

https://doi.org/10.1182/blood-2022-166636

Published: 2022

Journal Articles

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Jean-Hugues Dalle, Peter Bader, Akif Yesilipek, Franco Locatelli, Julia Palma, Jacek Wachowiak, Herbert Pichler, Marianne Ifversen, Gergely Kriván, Jochen Buechner, Cristina Díaz-de-Heredia, Marc Bierings, Raquel Staciuk, Tayfun Gungor, Jacek Toporski, Adriana Balduzzi, Ulrike Poetschger, Christina Peters, Petr Sedlacek

Blood (2022) 140 (Supplement 1): 903–905.

https://doi.org/10.1182/blood-2022-164735

Published: 2022

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Pantelia Roussou, Annie St. Pierre, Anirudh Prahallad, Cristina Díaz-de-Heredia

Blood (2022) 140 (Supplement 1): 1376–1378.

https://doi.org/10.1182/blood-2022-155708

Published: 2022

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-142397

Published: 2020

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

NARROW

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Treatment of Congenital Hypotransferrinemia Patients with Human Apotransferrin Resolves Anemia and Reduces Iron Accumulation

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only